Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd
688336
Classifica tra le azioni
#3774
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd functions as a... Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd functions as a biopharmaceutical enterprise operating in China. This company is thoroughly engaged in the full lifecycle of antibody-based medicines, from their initial research and development to their production and subsequent market introduction. Its current portfolio includes YISAIPU, a tumor necrosis factor inhibitor utilized for treating rheumatic ailments; Xenopax, a recombinant humanized anti-CD25 monoclonal antibody delivered via injection; and Cipterbin, an anti-HER2 monoclonal antibody. Furthermore, the organization is actively progressing novel treatments designed for autoimmune disorders, various cancers, and other health issues. Established in 2002, its main offices are situated in Shanghai, China.
Prezzo delle azioni
$4.87
Capitalizzazione di mercato
$4.36B
Variazione (1 giorno)
-5.47%
Variazione (1 anno)
-15.62%
Paese
CN
Scambia Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (688336)
Categoria
Healthcare
Utile per Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (688336)
Utile nel Jun 2026 TTM: $527.45M
Secondo gli ultimi rapporti finanziari di Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, gli utili attuali della società sono $527.45M. Nel 2024, la società ha registrato un utile di $96.95M, un aumento rispetto a agli utili del 2023, che erano di $43.88M. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Storico degli utili di Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd dal 2006 al 2026
Utile alla fine di ogni anno
| Anno | Utile | Cambia |
|---|---|---|
| 2026 (TTM) | $527.45M | 11.20% |
| 2025 | $474.32M | 389.24% |
| 2024 | $96.95M | 120.93% |
| 2023 | $43.88M | 945.41% |
| 2022 | $4.20M | -149.98% |
| 2021 | $-8.40M | -80.57% |
| 2020 | $-43.23M | -231.32% |
| 2019 | $32.92M | -44.95% |
| 2018 | $59.80M | -10.08% |
| 2017 | $66.50M | 49.67% |
| 2016 | $44.43M | 21.77% |
| 2015 | $36.49M | -8.05% |
| 2014 | $39.68M | -30.82% |
| 2013 | $57.36M | 23.82% |
| 2012 | $46.33M | 31.47% |
| 2011 | $35.24M | 34.54% |
| 2010 | $26.19M | 67.48% |
| 2009 | $15.64M | 79.66% |
| 2008 | $8.70M | 266.58% |
| 2007 | $2.37M | -158.83% |
| 2006 | $-4.04M | 0.00% |
Utile per aziende simili o concorrenti
| Azienda | Utile | Differenza negli utili | Il paese |
|---|---|---|---|
| $5.27B | 900.07% |
US
|
|
| $-3.09B | -685.26% |
US
|
|
| $-4.02B | -861.43% |
AU
|
|
| $3.01B | 469.85% |
BE
|
|
| $1.95B | 269.82% |
NL
|
